Corvus Pharmaceuticals, Inc.
CRVS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.75 | 0.07 | -0.02 | 0.11 |
| FCF Yield | -1.57% | -1.89% | -3.62% | -2.32% |
| EV / EBITDA | -57.57 | -29.00 | -22.78 | -44.28 |
| Quality | ||||
| ROIC | -14.53% | -12.56% | -19.66% | -24.06% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 50.00% |
| Cash Conversion Ratio | 0.94 | 0.72 | -0.54 | 0.70 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -62.41% | 29.03% | 1.96% | -33.92% |
| Safety | ||||
| Net Debt / EBITDA | 0.18 | 1.33 | 0.39 | 0.94 |
| Interest Coverage | -14.33 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -9,735.52 | -5,350.91 | -5,060.45 |